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Abstract
Development of efficient vectors for transfection is one of the major challenges in 
genetic engineering. Previous research demonstrated that cationic derivatives of 
polyisoprenoids (PTAI) may serve as carriers of nucleic acids. In the present study, 
the effectiveness of two PTAI-based formulations (PTAI-6–8 and 10–14) was inves-
tigated and compared to the commercial reagents. The purpose of applied gene ther-
apy was to enhance the expression of vascular endothelial growth factor (VEGF-
A) in the renal medulla of spontaneously hypertensive rats (SHR) and to test its 
potential as a novel antihypertensive intervention. In the first part of the study (in 
vitro), we confirmed that PTAI-based lipoplexes efficiently transfect XC rat sarcoma 
cells and are stable in 37 °C for 7 days. In the in vivo experiments, we administered 
selected lipoplexes directly to the kidneys of conscious SHR (via osmotic pumps). 
There were no blood pressure changes and VEGF-A level in renal medulla was sig-
nificantly higher only for PTAI-10–14-based formulation. In conclusion, despite 
the promising results, we were not able to achieve VEGF-A expression level high 
enough to verify VEGF-A gene therapy usefulness in SHR. However, results of our 
study give important indications for the future development of PTAI-based DNA 
carriers and kidney-targeted gene delivery.
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Development of efficient and safe vectors for transfection is one of the major chal-
lenges in gene therapy (Ramamoorth and Narvekar 2015). Two main classes are 
currently used: viral vectors and non-viral methods (Nayerossadat et  al. 2012). 
Virus-based vectors are considered more effective, but plagued by safety con-
cerns, due to their immunogenicity and cytotoxicity (Jafari et al. 2012). Several 
studies indicate that cationic lipids enhance the efficiency of nucleic acids and 
drug delivery to the cells (Namiki et  al. 2011; Jafari et  al. 2012). Lipid‐based 
carriers are known for their safety, versatility, low immunogenicity, simplicity 
of application, and easy modification for specific conditions (Wang et al. 2013). 
Cationic lipids interact spontaneously with negatively‐charged nucleic acids and 
form lipoplexes (complexes of lipids and DNA). Addition of neutral lipids (also 
called helper or co‐lipids), such as l-α-phosphatidylethanolamine dioleyl (DOPE) 
or cholesterol, change the properties of lipoplexes making them more suitable 
for some applications. Cholesterol is often suggested as a good helper lipid for 
in vivo use. Despite the fact that numerous cationic and helper lipids have been 
synthesized (many of them being the subjects of patent applications (Koynova 
and Tenchov 2011), none of the developed lipofecting agents appear to be perfect. 
As a result, intensive research has been carried out aiming to elaborate an optimal 
lipofecting formulation.
Polyisoprenoid alcohols (polyprenols and dolichols) are long chain, linear 
polymers composed of isoprene units [from several up to more than 100 units, 
(Swiezewska and Danikiewicz 2005)] found in almost all living organisms 
(Skorupinska-Tudek et al. 2008). They are involved in cell response to environ-
mental stress, glycosylation, and prenylation of proteins, and also they intensify 
the fusion and increase the permeability of model membranes (Swiezewska and 
Danikiewicz 2005). Recent studies (Gawrys et  al. 2014b, 2018; Grecka et  al. 
2016; Rak et al. 2016; Stachyra et al. 2017) show that cationic derivatives of pol-
yisoprenoid alcohols, called PTAI, are non-toxic and may serve as lipofectants. 
In the present study, the effectiveness of two PTAI mixtures was investigated for 
plasmid DNA delivery into rats’ cells and to rats and compared to the commer-
cially available reagents for transfection: in vivo-jetPEI® (Polyplus-transfection) 
and Avalanche®-in vivo Transfection Reagent (EZ Biosystems LLC).
PTAI-based reagents were used to enhance the expression of vascular endothe-
lial growth factor type A (VEGF-A) in spontaneously hypertensive rats (SHR). 
Hypertension is a worldwide health problem, because of its high prevalence and 
associated renal and cardiovascular diseases, such as chronic kidney disease, 
heart failure, ischemic heart disease, stroke and other cerebrovascular or retinal 
diseases (Chockalingam et  al. 2006; World Health Organization 2013). Despite 
decades of research, hypertension is still inadequately diagnosed, largely because 
of incomplete understanding of the underlying pathogenic mechanisms. Recent 
studies provide an ample evidence supporting an important role of VEGF defi-
ciency in the development of hypertension and related kidney diseases (Bhar-
gava 2009; Chade 2016). VEGF is a principal regulator of various physiological 
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processes including angiogenesis, mediating increased vascular permeability, 
proliferation, and lymphangiogenesis (Robinson et al. 2010). The first indication 
of an association of VEGF-A and hypertension was when VEGF inhibitors were 
applied for anticancer therapy. In all cases of inhibition of the VEGF signaling 
pathway, hypertension was the most common side effect [currently it occurs in 
up to 80% of patients treated with these drugs (Bhargava 2009; Robinson et  al. 
2010)]. The mechanism of hypertension associated with VEGF inhibition is still 
not clear and it is uncertain what is crucial for the development of suitable thera-
peutic strategies for patients (Chade 2016).
The aim of presented study was to evaluate if enhanced expression of VEGF-A in 
the renal medulla—crucial area for renal blood pressure regulation (Cowley 2008) 
will increase its circulation and reduce blood pressure of hypertensive rats.
Materials and Methods
Plasmids
The reporter plasmid pEGFP‐C1 encoding enhanced green fluorescent protein 
(eGFP) was kindly supplied by Professor A. F. Sikorski (University of Wrocław, 
Poland). Plasmid encoding rat vascular endothelial growth factor A (rVegf), tran-
script variant 1, NM_001287107.1 was purchased from OriGene (Rockville, MD, 
USA). The rVegf cDNA was PCR amplified, purified using GeneMATRIX DNA/
PCR Clean-up Purification Kit (Eurx, Gdansk, Poland), and ligated (T4 DNA Ligase; 
Invitrogen/Thermo Fisher Scientific; Waltham, MA, USA) to plasmid #67275 (a 
gift from Jannik Elverløv-Jakobsen, Addgene; Watertown, MA, USA) after dele-
tion of TurboFP with PacI and XhoI restriction enzymes. mCherry sequence was 
PCR amplified from pLV-mCherry #36084 plasmid (RRID:Addgene_36084; a gift 
from Pantelis Tsoulfas, Addgene) and cloned to the #67275-rVEGF using AgeI and 
ClaI restriction sites, creating pCAG-rVegf-2A-mCherry plasmid. Control plasmid, 
pCAG-mCherry, containing only mCherry expression cassette was generated by 
PCR amplification of mCherry and cloning into #67275 plasmid using PacI and ClaI 
restriction sites.
All amplification reactions were performed using Phusion HF polymerase 
(Thermo Fisher Scientific) and all restriction enzymes were purchased from New 
England Biolabs (Ipswich, MA, USA). Plasmid sequences were verified by restric-
tion analysis and DNA sequencing (Genomed, Warsaw, Poland).
PTAI Chemical Synthesis and Purification
Trimethylpolyprenylammonium iodides (PTAI, Fig.  1) were prepared from natu-
rally occurring polyprenols according to Madeja et  al. (2007) with modifications. 
Two types of PTAI preparations with different length polyprenoid chains were used 
in this work: PTAI-6–8 and PTAI-10–14, containing a mixture of polyprenols with 
chain lengths from 6 to 8 or 10 to 14 isoprene units, respectively. All polyprenols 
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used for the synthesis of cationic derivatives were from the Collection of Polypre-
nols, Institute of Biochemistry and Biophysics PAS, Warsaw. The relevant prepara-
tion procedures have been described in a patent (No. 211824, Polish Patent Office 
2012). All products were stable as demonstrated by thin layer chromatography on 
silica gel plates (Merck, Darmstadt, Germany), which showed single spots in chloro-
form/methanol/water (65:25:4,; Rf = 0.66); in n-butanol/acetic acid/water (66:17:17; 
Rf = 0.23); in n-propanol/ammonia/water (8:1:1; Rf = 0.10) , and in ethyl acetate/
methanol/acetic acid (75:20:5; Rf = 0.03). No symptoms of decomposition were 
detected for any of the compounds after 1  year of storage in a dry state in argon 
atmosphere at – 80 °C.
Preparation of Reagents Based on PTAI
PTAIs (PTAI-6–8 and -10–14) and helper lipids (Sigma-Aldrich, St. Louis, 
USA) l-α-phosphatidylethanolamine dioleyl (DOPE) and 3ß-[N-(N′,N′-
dimethylaminoethane)-carbamoyl]cholesterol hydrochloride (DC-cholesterol; DC-
CHOL) were dissolved in ethanol (99%). The following two compositions contain-
ing PTAI and helper lipids in ethanol at the indicated molar ratios were prepared: 
PTAI-6,7,8+DOPE—1.5:1 and PTAI-10–14+DOPE+DC-cholesterol—1:1:1. 
Obtained mixtures were mixed with DMEM F-12 HAM cell culture medium with-
out additions of serum and antibiotics and intensely vortexed for 3  min. Ethanol 
content in the mixtures was PTAI-6–8/DOPE—11,4% and PTAI-10–14/DOPE/
DC-cholesterol—20.7%. The compositions were stored at 4 °C up to 7 days. These 
compositions were previously shown to be effective DNA vaccine carriers (Stach-
yra et al. 2017). They (and their use) are the subject of patents (No. 231158, Polish 
Patent Office 2019; No. 230096, Polish Patent Office 2018) and patent application 
(No. PCT/PL2015/000093, WO/2016/032348, Polish Patent Office, European Patent 
Office).
In Vitro Transfection Efficiency
Cell Culture
Rat sarcoma XC cells (ATCC Cat# CCL-165, RRID:CVCL_1891) were cultured in 
DMEM Low-Glucose medium (Sigma-Aldrich, St. Louis, USA) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; Gibco Lab., New York, USA). Media 
were supplemented with 100  IU/ml penicillin and 10  µg/ml streptomycin (Polfa, 
Tarchomin, Poland) and cells were cultured in a humidified atmosphere with 5% 
 CO2 at 37  °C. For transfection experiments, cells were seeded into the wells of a 




24-well plate at a density of 8 × 104 cell/well and cultivated for 24 h in media with 
10% FBS without antibiotics (to reach 70–80% confluence).
PTAI-6–8/DOPE and PTAI-10–14/DOPE/DC-cholesterol mixtures were diluted 
in serum‐free and antibiotic-free cell culture medium or 5% glucose and mixed with 
pEGFP‐C1 plasmid diluted in cell culture medium or 5% glucose, respectively, to 
final concentration of 0.2 μg/μl. Next, they were incubated for 30 min at room tem-
perature to obtain lipoplexes and diluted in serum‐free DMEM F12 HAM medium 
(1:4). 2.5  μg of PTAI- 6–8/DOPE and 4  μg of PTAI-10–14/DOPE were used for 
transfection of cells per well of 24-well plate. Lipids and pDNA were mixed at 
calculated ± charge ratio of 1:2.0 for PTAI-10–14 and 1:2.3 for PTAI-6–8-based 
lipoplexes.
The Transfection Efficiency of PTAI in Glucose Medium
The transfection efficiency was calculated after 24  h of cell incubation with lipo-
plexes. Cells were washed with phosphate-buffered saline (PBS), incubated in the 
presence of Hoechst 33342 (1 µg/ml in PBS; Sigma-Aldrich, St. Louis, USA) for 
10 min, washed again with PBS, and submerged in DMEM Low-Glucose medium 
with 10% FBS. The percentage of transfected cells was calculated under fluorescent 
Leica DMI6000B AF7000 microscope (Leica Microsystems GmbH, Wetzlar, Ger-
many) according to the following formula:
where NmCh is the number of cells expressing mCherry and NHoe is the number of 
cells stained with Hoechst 33,342.
Prolonged Stability of PTAI‑Based Lipoplexes
Stability and effectiveness of the PTAI-based lipoplexes after incubation in 37 °C up 
to 7 days was tested in vitro. Transfection mixtures were prepared as described for 
osmotic pumps administration (see below). In the serum-free procedure, the medium 
from cells was aspirated and replaced with 300  µl of serum-free DMEM Low-
glucose medium and 100 µl of the lipoplexes suspension containing 3 µg of lipids 
[FBS(−); serum-free conditions]. In the presence of serum procedure [FBS(+)], 
200 µl of medium was left in the well and 100 µl of the lipoplexes suspension was 
added together with 100 µl of medium without serum and antibiotics. After 5 h of 
incubation at 37  °C in 5%  CO2, 400 µl of DMEM Low-Glucose medium supple-
mented with 20% of FBS and antibiotics was added to the transfection medium.
Flow Cytometry Analysis
For flow cytometry analysis, cells were washed with phosphate-buffered saline (PBS) 
and harvested with 0.25% trypsin with 0.02% EDTA. For GFP reporter analysis, cells 









easyCyte 8 flow cytometer (Luminex, Austin, TX, USA), with 488 nm laser excitation. 
The percentage of GFP-positive cells was analyzed by InCyte software ver. 3.3 (Luminex, 
Austin, TX, USA) and presented as average from each group with SEM values.
For mCherry analysis, Amnis ImageStream® X MkII imaging cytometer (Luminex, 
Austin, TX, USA) was utilized. This unique system allows not only to perform high-
throughput, quantitative multi-parameter flow cytometry measurements with high 
sensitivity, but additionally, based on advanced charge-coupled device (CCD) cam-
era imagery features, it simultaneously collects galleries of single objects in up to 12 
channels. Thus, this high-end system combines the speed and statistical significance of 
flow cytometry with the power of fluorescent microscopy, allowing to perform sophis-
ticated morphometric analyses of signal distribution, on single cell as well as on whole 
population level. For cell acquisition, INSPIRE® software (Luminex, Austin, TX, 
USA) was used, with 561 nm laser excitation and ×40 magnification objective. Data 
were analyzed using IDEAS® software ver. 6.2 (Luminex, Austin, TX, USA).
In Vivo
Preparation of the Transfection Mixtures for In Vivo Experiments
Two PTAI compositions were prepared as described above. Two commercially 
available reagents were used: Avalanche®-in vivo Transfection Reagent (cat. no 
EZT-VIVO-1, EZ Biosystems LLC, Maryland, USA) and in vivo-jetPEI® (cat. no 
201-10G, Polyplus-transfection S.A, Illkirch, France). The reagents were handled 
according to the manufacturer’s instructions.
For intravenous infusion (I), appropriate amount of plasmid DNA (150–180 µg 
per intravenous injection, see Table 1 for details) was diluted with ultrapure MiliQ 
water and 10% sterile glucose to obtain ½ injection volume (5% final glucose con-
centration). PTAI-10–14-based lipoplexes were prepared at ± charge ratio of 1:1.7. 
The appropriate amount of reagent for transfection also was diluted with sterile 10% 
glucose and MiliQ water to achieve ½ injection volume (5% final glucose concentra-
tion). Then both solutions were mixed together and incubated for 15–30 min (room 
temp.).
For osmotic pumps administration (II), 100 µg of the nucleic acid was used for 
one osmotic pump (for pump details see below Intrarenal infusion with ALZET® 
Osmotic Pumps), hence each rat received 200 µg of DNA in total (to both kidneys). 
The DNA to reagent ratio was as follows: 0.5 µl of PTAI-10–14, 0.6 µl of PTAI-6–8 
and 0.14 µl for jetPei®, and Avalanche per 1 µg DNA (± charge ratio of 1:2.0 for 
PTAI-10–14 and 1:2.3 for PTAI-6–8-based lipolexes). The preparation of the solu-
tions was as described above for intravenous injection. Control group of animals 
received osmotic pumps filled only with the solvent (sterile 5% glucose without 
DNA and without any reagent for lipofection). Filled osmotic pumps were started-up 
by incubation in 37 °C overnight in sterile 0.9% saline before implantation. This step 
is essential when catheters are used to minimize the chance of an occlusion or clot 




The experimental procedures were approved by the I Ethical Committee for Animal 
Experimentation (Warsaw), which follows the European Directive 2010/63/EU on 
the protection of animals used for scientific purposes (no 34/2015, 479/2017). Male, 
adult (16 weeks old, mean body weight 299 ± 4 g) spontaneously hypertensive rats 
(SHR) bred at the Animal House of Mossakowski Medical Research Centre, Polish 
Academy of Sciences (n = 44) were fed ad libitum a standard diet (STD, 0.25% Na 
w/w, SSNIFF GmbH, Soest, Germany) and had free access to drinking water during 
the whole experiment. Animals were housed 2 per cage in a conventional animal 
room with controlled temperature (24 ± 2 °C) and a 12/12 h light–dark cycle.
Protocols
The study was divided into two protocols. The first set of experiments was to choose 
the optimal conditions for transfection and to evaluate and compare the effective-
ness of selected PTAI and commercial reagents for DNA delivery after intravenous 
administration (I, n = 21). In the second phase, we wanted to evaluate the impact 
of enhanced expression of VEGF-A administered directly into the renal medulla of 
adult SHR with ALZET® Osmotic Pumps (II, n = 23).
Intravenous Injection (I)
In the preliminary experiments, various conditions were tested (summarized in 
Table 1) i.e., the DNA:reagent ratio (from 0.12 to 0.20), number of injections, and 
duration of the observation (24–72 h). The intravenous infusions to adult SHR were 
conducted under isoflurane anesthesia (IsoVet®, Piramal Healthcare, UK) at 4% in 
the induction phase and maintained by mask inhalation at 2–1.5% during the pro-
cedure (Combi-vet® system, Rothacher Medical GmbH, Heitenried, Switzerland). 
Lipofecting solutions (1 ml) containing appropriate reagent for transfection mixed 
with plasmid DNA were infused via tail vein at a rate of 6 ml/h for 10 min. After 
awakening from anesthesia, rats were observed for 24, 48, or 72 h (Table 1). Then all 
rats were anaesthetized with intraperitoneal sodium thiopental (Thipen®, 100 mg/
kg; Samarth Life Sciences Pvt. Ltd, Baddi, India) and perfused with PBS. Fragment 
of the spleen, liver, lung, and whole kidney were collected and kept in ice-cold PBS 
until flow cytometry measurement (analysis of fluorescence of the reporter protein 
was performed on the same day). Another fragment of the spleen, liver, lung, heart, 
brain, and the second kidney were frozen in dry ice for further microscopic analysis 
(− 80 °C).
Intrarenal Infusion with ALZET® Osmotic Pumps (2 Week Observation, II)
SHR (n = 23) were implanted with telemetry transmitters (Data Sciences Interna-
tional, St. Paul, USA) for blood pressure measurements. The procedure was con-
ducted under isoflurane anesthesia (see above). After 7 days of recovery, rats were 
randomly divided into five groups and again under isoflurane anesthesia were 
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implanted with osmotic pumps (model 2001, release rate 1 µl/h, duration 1 week, 
reservoir volume 200  µl, ALZET® Osmotic Pumps, Cupertino, USA). To each 
osmotic pump, a catheter was attached connected to ALZET Brain Infusion Kit 2 
(ALZET® Osmotic Pumps, Cupertino, USA) allowing the infusion of selected solu-
tions into the renal medulla. Flank incision was made and the kidney was exposed. 
The 3 mm needle of the infusion kit was inserted into the renal medulla (on the bor-
der on the outer and inner medulla of the kidney) and secured with tissue glue (His-
toacryl®, Braun Surgical S.A. Rubi, Spain). The incision was closed with sutures 
and the procedure was repeated for the second kidney (each rat received two mini-
osmotic pumps).
Blood pressure (BP) was measured before the implantation of the osmotic pumps 
(day 0) and on 1, 4, 8, 10, and 14th day of the observation, starting at 3 pm and fin-
ishing at 8 am on the next day. Urine samples were collected on days 0, 7, and 14th 
in metabolic cages (Tecniplast S.p.A. Buguggiate, Italy). After 2 weeks, rats were 
anaesthetized with intraperitoneal sodium thiopental and perfused with PBS. Half 
of one kidney was harvested and kept in ice-cold PBS until flow cytometry analysis. 
Second half was cut with surgical scissors to separate cortex and medulla, which 
were frozen separately in dry ice. Whole second kidney was harvested and frozen 
on dry ice. All frozen tissues were stored in − 80 °C until further analysis (ELISA, 
microscopic).
Tissue Homogenization and Flow Cytometry
Tissues were weighted and dissected with surgical scissors into 1 mm pieces and 
3 ml of preheated (37 °C) collagenase IV (0.15 PZ U/ml, SERVA Electrophoresis 
GmbH, Heidelberg, Germany) with 2 mM calcium chloride solution added to each 
sample. Tissues were incubated in 37 °C on rocking platform with gentle agitation 
(spleens for 10 min, kidneys for 15 min, livers for 30 min and lungs for 40 min). The 
enzymatic digestion was stopped by putting the solution on ice. Afterwards each 
solution was carefully pipetted back and forth for 15–20 times and filtered through 
70  µm nylon cell strainer, followed by centrifugation (300×g, 4  min). The super-
natant was discarded and cells were suspended in RBC lysing buffer for red blood 
cell removal. After 10 min incubation (room temp.), cells were centrifuged (300×g, 
4 min) and washed with FCM buffer. The fluorescence of reporter proteins (eGFP 
or mCherry) in obtained single cells suspension was analyzed on BD FACS Canto 
II flow cytometer (BD Biosciences, Poland). Just before the analysis, the cells were 
filtered again using Flowmi Cell Strainers for 1000 µl Pipette Tips (porosity 40 µm, 
Bel-Art—SP Scienceware, Wayne, USA).
The results were acquired and analyzed with Diva software (BD Biosciences, 
Poland). Forward scatter area (FSC-A) versus side scatter area (SSC-A) density plots 
were used for gating to exclude debris and identify cells of interest based on the size 
and granularity (gate P1). To exclude doublets, a forward scatter height (FSC-H) 
versus forward scatter area (FSC-A) density plots were constructed and single cells 
were gated (gate P2). Single parameter histograms were used to further identify dis-
tinct cells that express a reporter gene (eGFP or mCherry).
1 3
Biochemical Genetics 
VEGF‑A Concentration in Urine and Renal Homogenates
VEGF-A protein level was measured with commercial ELISA kit (cat no K5365, 
BioVision, Inc., San Francisco, USA) with detection range 15.6–1000 pg/ml accord-
ing to the manufacturer’s instruction. Kidneys (cortex and medulla separately) were 
weighted and mechanically homogenized in glass homogenizers in RIPA buffer 
(1 mg of tissue for 2 µl of the buffer, Sigma-Aldrich, Poland) with proteases inhibi-
tors (cOmplete™, Mini Protease Inhibitor Cocktail, Sigma-Aldrich, Poland). Renal 
homogenates were diluted 1:200, whereas urine was diluted 1:5 with provided sam-
ple diluent buffer. Total protein content in renal homogenates was measured with 
Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Poland) according to 
the attached instructions.
Chemicals and Buffers
RBC lysis buffer (10× concentration) for red blood cells removal was prepared 
by mixing 8.02  g of ammonium chloride  (NH4Cl), 0.84  g of sodium bicarbonate 
 (NaHCO3), and 0.37 g of EDTA (disodium) and the volume was adjusted to 10 ml 
with MiliQ water. Stock solution was stored at 4 °C and diluted (1:10 with MiliQ 
water) on the day of the analysis.
FCM buffer for flow cytometry analysis was prepared by mixing 2.5 g albumin 
fraction V (AppliChem GmbH, Darmstadt, Germany), 0.16  g EDTA (disodium), 
and 0.5 g sodium azide  (NaN3) and the volume was adjusted to 500 ml with PBS. 
The solution was stored at 4 °C for 6 months.
Statistics
Data are presented as the means ± SEM. The significance of changes was evalu-
ated by repeated measures multivariate analysis of variance (ANOVA), followed by 
a post hoc Duncan’s multiple range test. For some parameters, one-way ANOVA 
was used. In cases where the data did not meet the assumptions for ANOVA, non-
parametric tests were used (Kruskal–Wallis H test). All calculations were mad with 
STATISTICA software (version 10.0, StatSoft, Inc. Poland). The level of statistical 
significance was set at p < 0.05.
Results
In Vitro
In our previous studies we have shown that cationic polyisoprenoids are effective 
components of lipofecting mixtures (Rak et  al. 2016) and DNA vaccines vehicles 
(Stachyra et  al. 2017). In the present study, we have tested PTAI-6–8 and PTAI-
10–14 in mixtures with helper lipids in the in vitro model of XC rat Rous sarcoma 
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cell line before using these formulations in vivo in rats. Plasmid DNA pEGFP‐C1 
encoding reporter eGFP as well as plasmid DNA encoding mCherry reporter and 
VEGF-A protein were used to test in vitro efficiency of PTAI-based lipofecting mix-
tures. In our first experiments, we aimed at testing if efficiency of PTAI lipofect-
ing mixtures is the same after preparation of lipoplexes in culture medium and 5% 
glucose as planned for in vivo experiments. It was an inevitable step as the compo-
sition of solution used for lipoplexes preparation can influence its formation, sta-
bility ,and effectiveness. The results showed no statistically significant differences 
between lipoplexes prepared in these two different solutions (Fig. 2a and b). Both 
compositions also showed the same pattern of slightly lower lipofection efficiency 
in the presence of serum compared to serum-free conditions (not statistically sig-
nificant). Moreover, flow cytometry analysis was used to evaluate possible apoptosis 
signs after lipofection. Process of cell death causes changes in cellular morphology, 
resulting in cell shrinkage and fragmentation, which can affect scattering proper-
ties of cells analyzed by flow cytometry. In particular, due to the changes in cellular 
size and internal complexity, apoptotic cells typically possess decreased FSC sig-
nal, whereas their SSC signal increases. Thus, based on performed flow cytometry 
analysis of FSC and SSC parameters, we did not observe any significant changes in 
morphological characteristics of transfected cells that would indicate cell apoptosis 
(Supplementary Fig. S1).
In the second set of in vitro trials, we have tested the stability of lipoplexes at 
37 °C in the period of 7 days as planned for intrarenal infusion with osmotic pumps. 
Lipoplexes were prepared in 5% glucose solution. The results showed higher effi-
ciency of transfection for PTAI-10–14 composition (Fig. 2c, Supplemental Fig. S2) 
than PTAI-6–8. Both PTAI-6–8 and PTAI-10–14 compositions resulted in formula-
tion of lipoplexes that were stable at 37 °C for 7 days (Fig. 2c, Supplemental Fig. 
S2). PTAI-10–14-based composition showed high transfection efficiency both—in 
the absence and presence of serum, while PTAI-6–8-based formulation was more 
efficient in serum-free conditions than in the presence of serum. In this set of experi-
ments, manual counting of cells with fluorescent microscope was used. Additionally, 
the efficiency of PTAI-10–14-based composition stored at 37 °C was tested on the 
first day (24 h after preparation of lipoplexes) and on the 7th day by ImageStream® 
technology. The stability of lipoplexes (Fig. 2d, e) was confirmed, hence on the basis 
of the obtained results and our previous findings, which proved the activity of PTAI-
6–8 and PTAI-10–14-based compositions in vivo (Stachyra et al. 2017), both formu-
lations were chosen for further experiments.
In Vivo
Intravenous Injection
In the preliminary study, we wanted to compare selected reagents based on PTAIs to 
commercial carriers for transfection and to choose the optimal conditions for further 
experiments. Unfortunately, we were not able to obtain satisfactory results with any 
1 3
Biochemical Genetics 
Fig. 2  Efficiency of DNA transfer into XC cells in the presence (FBS+) and absence (FBS-) of serum with 
PTAI-based lipoplexes. a, b XC cells transfected with PTAI-10–14+DOPE+DC-cholesterol using pEGFP-C1 
plasmid, lipofecting mixtures prepared in cell culture medium (med), or 5% glucose solution (glu) and used 
in the absence FBS (−) or presence FBS (+) of serum, a—representative images, b—efficiency of lipofec-
tion evaluated by flow cytometry; each value represents the mean ± SEM (n = 6); c–e XC cells transfected with 
PTAI-6–8+DOPE and PTAI-10–14+DOPE+DC-cholesterol using mCherry-VEGF-A plasmid with lipoplexes 
prepared in 5% glucose and stored at 37 °C for 1–7 days (day 0—lipoplexes used after preparation, not stored, 
days 1–7—lipoplexes stored for 1–7 days); c—efficiency of lipofection counted using fluorescence microscope, 
each value represents the mean ± SEM (n = 3); d—no loss of efficiency of PTAI-10–14-based lipoplexes, data 
shown as % of control on day 0 evaluated with ImageStream® X MkII system; e—representative images of cells 
obtained based on the ImageStream® X MkII analysis at day 0 and day 7. Exemplary galleries of cells in bright 
field (BF) and mCherry fluorescence channel were presented; a–e molar ratios: PTAI-6–8+DOPE—1.5:1 and 
PTAI-10–14+DOPE+DC-cholesterol—1:1:1, PTAI+DOPE concentration: PTAI-6–8-based lipoplexes—4  µg/
well of 24-well plate, PTAI-10–14-based lipoplexes—4 µg/well of 24-well plate, DC-cholesterol added as addi-
tional lipid at indicated molar ratio; * p < 0.05, non-parametric Kruskal–Wallis H test
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tested reagents. The fluorescence resulting from the expression of the reporter gene 
(eGFP or mCherry) was undetectable in almost all tissues (regardless of the different 
conditions and reagents tested; data not shown). Only in the liver, there were traces 
of reporter protein fluorescence (Table  1) with commercially available reagents 
(Avalanche and jetPei®). The representative flow cytometry analysis for each group 
is depicted in Fig. 3a–d. Interestingly, there was no correlation between the amount 
of applied DNA with the efficiency of transfection. Similar level of reporter protein 
fluorescence in the liver was observed after one and two injections. However, the 
administration of 180 µg of DNA at once (during 10 min infusion) seemed to cause 
slight toxic effect on the rat. The animal was lethargic for few hours and porphyrin 
staining was observed around the nose and eyes of the rat, which might indicate 
stress or sickness. The toxic effect was transient and rats’ behavior and appearance 
returned to normal on the next day.
Table 1  Summary of the preliminary in  vivo experiments in which various conditions were tested for 
transfection after intravenous administration (individual subjects)
























eGFP 150 27 0.18 1 150 48 29.8
150 30 0.20 2 300 48 31.3
150 18 0.12 2 300 48 34.3
mCherry 150 30 0.20 1 150 48 42.0 (A)
150 30 0.20 1 150 24 51.0
150 30 0.20 2 300 48 39.8
180 30 0.17 1 180 72 32.5
jetPei® mCherry 150 21 0.14 1 150 48 33.4
150 27 0.18 1 150 48 35.4 (B)
– – 27 – 1 – 48 13.6
PTAI
-10–14
eGFP 150 90 0.60 1 150 24 8.2
mCherry 150 90 0.60 2 300 48 7.6 (C)
150 90 0.60 1 150 24 7.6
5% glucose – – 1 – 48 11.1
2 48 17.7






PBS – – 1 – 24 12.2
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Intrarenal Infusion with ALZET® Osmotic Pumps (2 Week Observation)
Since intravenous delivery of DNA complexes was unsuccessful, we changed the 
route of administration to intrarenal. All rats were in a good health and no signs of 
toxicity were observed. All animals demonstrated normal weight gain which was not 
influenced by administered substances. Also diuresis, water, and food intake were 
Fig. 3  Representative flow cytometry analysis of fluorescence of mCherry in liver tissue homogenized to 
single cell suspension after intravenous injection of lipofection mixtures containing plasmid DNA mixed 




similar in all groups and the values were within the normal range for adult SHR 
(data not shown). Mean blood pressure (MBP) was not affected during the 2 week 
observation (Fig. 4).
The level of VEGF-A was measured in urine and in renal homogenates (Fig. 5a and 
b). Only slightly higher urinary excretion of VEGF-A protein was observed after plasmid 
administration with Avalanche® reagent compared to other treatments; however, the dif-
ference was not statistically significant. The level of VEGF-A in the renal cortex was sta-
tistically higher in all groups receiving plasmid DNA with VEGF-A gene in comparison 
Fig. 4  Mean blood pressure (MBP) of adult SHR receiving plasmid DNA encoding VEGF-A gene in 
osmotic pumps (model 2001) directly into the renal medulla mixed with different reagents for transfec-
tion: PTAI-10–14 (n = 4); PTAI-6–8 (n = 4); Avalanche® (n = 5); in  vivo-jetPEI® (n = 5); 5% glucose 
(control group, n = 5); NS
Fig. 5  a Urinary excretion of VEGF-A and b VEGF-A level in the renal medulla and cortex of adult 
SHR receiving plasmid DNA encoding VEGF-A gene in osmotic pumps (model 2001) directly into the 
renal medulla mixed with different reagents for transfection: PTAI-10–14 (n = 4); PTAI-6–8 (n = 4); Ava-
lanche® (n = 5); in vivo-jetPEI® (n = 5); 5% glucose (control group, n = 5); *p < 0.05 values in all groups 




to control group, which received only solvent solution (5% glucose). In renal medulla, 
only after PTAI-10–14-DNA delivery, statistically higher level of VEGF-A protein was 
observed in comparison to control group which received glucose (Fig. 5b).
Flow cytometry analysis revealed no traces of mCherry fluorescence measured 
in single cell suspensions of homogenized kidneys. Results showed no differences 
between groups receiving plasmid DNA with different lipofectants (commercial and 
PTAI-based) and in comparison to control group which received only 5% glucose 
(data not shown).
Discussion
Advances in gene delivery technology and progresses in understanding pathogenesis 
of various diseases resulted in implementation of the first clinical trials with thera-
peutic nucleic acids (Sridharan and Gogtay 2016). The major obstacle is the lack 
of efficient and safe DNA carriers (Ramamoorth and Narvekar 2015). Among the 
non-viral methods, lipofection is considered as one of the most promising option. 
Previous studies showed that new type of cationic lipids, called PTAI constitute a 
promising alternative in formulating new lipofecting agents. Lipofecting activ-
ity of PTAI allows to effectively transfect plasmid DNA into cells without signifi-
cant side effects on cell physiology (Grecka et al. 2016; Rak et al. 2016; Stachyra 
et al. 2017). Moreover, compositions of PTAI and different co-lipids enable DNA 
and RNA transfer into a wide range of cell types both in the presence and absence 
of serum. Developed lipoplexes are non-toxic for rats (Gawrys et al. 2014a, b), are 
safe towards human RBSs and are effective DNA vaccines and drug carriers in vivo 
(Grecka et al. 2016; Rak et al. 2016; Stachyra et al. 2017; Gawrys et al. 2018). All 
these finding resulted in 3 received polish patents (PL 231158, 2019; PL 230096, 
2018; PL 211824, 2012) and 1 international patent application (WO/2016/03234 8, 
PCT/PL2015/00 0093, pending) making PTAI an interesting choice in lipofection.
In Vitro Efficiency and Stability Tests
The in vitro tests of PTAI-based lipofecting reagents were designed to evaluate if PTAI 
lipoplexes could be adjusted to in vivo administration in 5% glucose solution for single 
injections and for prolonged administration in osmotic pumps. Obtained results showing 
that 5% glucose solution is a suitable medium for PTAI-based lipoplexes preparation are 
in accordance with data previously shown in the literature that this solution is favorable 
for in vivo and in vitro nucleic acids delivery systems (Phua et al. 2013; Tao et al. 2016). 
Moreover, some data were also showing that glucose solution causes formation of smaller 
and more effective (especially in the presence of serum) lipoplexes (Sakaguchi et  al. 
2008). Additionally, glucose solutions are also recommended for in vivo transfections by 
producers of commercially available transfecting agents. In conclusion PTAI-based for-
mulations can be prepared in 5% glucose exhibiting high efficiency of lipofection.
Stability of the formulation is a crucial issue, as lipoplexes structure pro-
tects DNA from degradation and determines the interactions with cell membrane. 
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Lipoplexes stability in aqueous solutions is usually tested during hours (usually 
4–5 h) after preparation—to ensure that they are stable within the time of incubation 
with cells. Commercially available lipofecting agents are stored in a form not mixed 
with nucleic acids and at lower temperature (4 °C). There are some trials to imple-
ment dehydration method for the storage of transfecting agents already complexed 
with nucleic acids (Kasper et al. 2011; Perche et al. 2012), which could be beneficial 
for many applications, such as storage of DNA vaccines. Nevertheless, high sensi-
tivity of lipids and DNA to hydrolysis and oxidative degradation is underlined as 
the main obstacle in achieving stable and effective lipoplexes for prolonged storage 
(Varshney and Singh 2015). Thus, lipoplexes are usually only expected to be stable 
in cell culture medium for a few hours to interact with cell membrane in vitro or in 
the blood stream after in vivo injections. Testing stability of lipoplexes suspended 
in aqueous solutions and kept at 37 °C is unusual in literature. Planned delivery in 
osmotic pumps constituted a new challenge in the process of development of PTAI-
based lipofectants. PTAI-based lipoplexes were proved to be stable not only in an 
aqueous solutions, but also at 37  °C for the period of 7 days, which constitutes a 
very promising option for prolonged drug delivery methods.
Usage of osmotic pumps is not common for DNA delivery. Some studies with 
osmotic mini-pumps showed that continuous intracerebral delivery of lipoplexes 
caused tumor regression (Samal and Dubruel 2015), which confirms the poten-
tial of osmotic pumps for targeted gene delivery. Demonstrated stability of PTAI-
based lipoplexes makes them perfect candidates for future application with osmotic 
pumps without necessity of using additional, complicated steps, such as dehydration 
method. Results obtained in vitro and our previous findings (Grecka et al. 2016; Rak 
et al. 2016; Stachyra et al. 2017) gave us a good basis for in vivo experiments, ensur-
ing administration of effective and stable PTAI-based lipoplexes.
In Vivo
The goal of the first part of the in vivo study was to evaluate the effectiveness of 
PTAIs as DNA carriers, therefore we wanted to compare their efficiency to com-
mercially available reagents for transfection. This part of the project proved to be 
more difficult than expected, because none of the applied reagents produced any 
satisfactory results. Out of two selected commercial reagents none provided sta-
ble and high expression of the reporter gene after intravenous administration. Both 
Avalanche®-in vivo Transfection Reagent and in vivo-jetPEI® are advertised as an 
extremely powerful reagents for in vivo delivery of any nucleic acid and to any ani-
mal model. Both products are based on cationic lipids or polymers, which accord-
ing to the manufacturers assurances, should provide formation of the stable com-
plexes with nucleic acids, protecting it from degradation and facilitating its delivery 
into the cells. For Avalanche® only a single successful report has been published 
so far describing the effect of MYO3A gene knockdown on breast cancer metastasis 
(Baghel et al. 2016). The authors injected female BALB/c mice intratumorally with 
MYO3A-directed shRNA. The injections were performed three times a week at a 
dose of 10 µg of shRNA mixed with 2 µL of the reagent in 50 µL of 5% glucose. 
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In case of in vivo-jetPEI® the manufacturer assures on the product website that its 
proven track record is supposedly over 700 publications. In fact there is a “Poly-
plus-transfection Database”, which is quite accessible and easy to use. After selec-
tion of the in vivo-jetPEI® reagent and DNA as a type of nucleic acid there is 23 
publications, which relate to intravenous infusion, however none of them in the rat. 
The majority of records describe studies in mice. Both manufacturers stipulate that 
the amount of nucleic acid must be determined according the administration route 
and the animal model and furthermore that the user need to optimize the amount 
of nucleic acids and its ratio to the reagent. Both product manuals include similar 
guidelines and starting conditions, which comprise of around 150 μg nucleic acid 
and 24–30 μl of the reagent in 1 ml of 5% glucose for intravenous infusion in the 
rat. In the present study we tried various conditions based on the given instructions 
(summarized in Table 1), unfortunately none produced any satisfactory results. Only 
in the homogenized liver there were some traces of the reporter protein fluorescence, 
achieved only with commercial reagents; however there was no correlation between 
the amount of applied nucleic acid, amount of injections or duration of the observa-
tion with the efficiency of transfection.
The observed results are somehow surprising, not only due to very low efficiency 
of all reagents, but also because there were no traces of fluorescence of the reporter 
gene in the lungs. All used reagents, commercial Avalanche® and in vivo-jetPEI®, 
as well as polyisoprenoid PTAI are cationic compounds, which should form com-
plexes with nucleic acids, called lipoplexes (i.e., Avalanche® and PTAI) or poly-
plexes (in vivo-jetPEI®, which is built of linear polyethylenimine). It has been 
reported that lipoplexes are accumulated in the lungs after intravenous administra-
tion, due to electrostatic interactions between positive charges of complexes and 
negatively charged erythrocytes. These interactions may cause agglutination (parti-
cles clumping), which in turn might cause the entrapment of complexes in the lungs 
(Eliyahu et al. 2002; Simberg et al. 2003; Hattori et al. 2019). Due to this phenom-
ena gene therapy for lung diseases lately gain significant importance (Kuruba et al. 
2009; Merkel and Kissel 2012; McCaskill et  al. 2013; Merkel et  al. 2014). How-
ever it also has been reported that the lung uptake and the bio-distribution of the 
complexes after systemic delivery depend on numerous factors, especially the helper 
lipids used in the formulations (Liu et al. 1997; Sakurai et al. 2001).
Due to lack of satisfactory results after systemic administration we decided to 
change the route of administration from intravenous to intrarenal. We expected that 
such targeted therapy with much higher concentration of DNA administered chroni-
cally over prolonged period will turn out to be more fruitful for hypertension treat-
ment. PTAI complexes were tested in the temperature of 37 °C and were proved to 
be stable and efficient after 7 days of incubation. Also, according to the manufactur-
ers assurances, in vivo-jetPEI® can be used in osmotic pumps for chronic adminis-
tration. This reagent was also used for intra-medullar administration in rats. Liu et al. 
(2008) used it for plasmid shRNA (100 μg) injection through catheter implanted into 
the renal medulla of male Sprague–Dawley rats. Moreover transfection with in vivo-
jetPEI® in Dahl S rats was described too. Left kidney was transfected with plas-
mid DNA (50 μg) in combination with ultrasound treatment (Wang et al. 2010; Zhu 
et al. 2012). The authors claim that ultrasounds significantly enhance the efficiency 
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of transfection with various reagents, including in vivo-jetPEI® (Hosseinkhani et al. 
2005; Newman and Bettinger 2007; Li et al. 2008), while Polyplus-transfection sup-
port team assures that their reagent should work without ultrasounds. Unfortunately 
this also proved to be untrue at least in our hands. Flow cytometry analysis did not 
show any signs of reporter protein fluorescence in the kidneys.
Only application of PTAI-10–14 to deliver plasmid DNA resulted in higher med-
ullary content of VEGF-A protein, which suggest its potential for in vivo gene deliv-
ery. However, in this group of rats (or any other) we did not observe any decrease 
in blood pressure. The level of expressed VEGF-A might be still too low to provoke 
the blood pressure change or its role in the control of blood pressure is not as crucial 
as initially suggested in this model of hypertension; however this question still needs 
to be answered in further studies.
Conclusions
Conducted in vitro experiments showed that PTAI-based lipoplexes efficiently trans-
fect XC rat sarcoma cells. Moreover, preparation of lipoplexes in 5% glucose solu-
tion for in vivo application (instead of cell culture medium for in vitro use) did not 
change the efficiency of DNA transfer. PTAI-based lipoplexes were also stable when 
stored at 37 °C for 7 days, which makes them suitable for prolonged DNA delivery 
in osmotic pumps.
After in  vivo intravenous injection to SHR, only weak fluorescent signal of 
reporter protein mCherry for Avalanche® and jetPei® in the liver was observed. 
Prolonged 7-day intrarenal infusion with osmotic pumps resulted in slightly higher 
urinary excretion of VEGF-A for Avalanche® reagent (NS). Interestingly, VEGF-
A level in renal medulla was significantly higher only for PTAI-10–14-based 
formulation.
In conclusion, despite the promising in vitro results, we were not able to achieve 
VEGF-A expression level high enough to verify VEGF-A gene therapy usefulness in 
SHR model. However, results of our study give important indications for the future 
development of PTAI-based DNA carriers and kidney-targeted gene delivery. Based 
on our research on three lipid-based and one polymer-based transfection reagents, 
we conclude that other factors such as ultrasounds or suction-mediated transfection 
(Taniguchi et  al. 2016; Oyama et  al. 2017) may be necessary to achieve efficient 
transfection in SHR model of hypertension.
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